Trial Profile
A Randomized Phase II Study of Anlotinib Combined With Pemetrexed and Cisplatin in First Treatment for Advanced Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Negative Mutations
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Cisplatin (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Jan 2021 Status changed from not yet recruiting to recruiting, according to Trial design presented at the 2020 World Conference on Lung Cancer
- 31 Jan 2021 According to Trial design presented at the 2020 World Conference on Lung Cancer, 18 patients have been enrolled in the study (until June 26, 2020).
- 31 Jan 2021 Trial design presented at the 2020 World Conference on Lung Cancer